Trial: 202201124

A Phase 1b, Open-label, Dose-escalation Trial Of The Safety Of And Antigen-specific Immune Responses Elicited By Vb.10 Neo In Combination With Atezolizumab In Subjects With Locally Advanced And
Metastatic Tumors

Phase

I (Cancer Control)

Principal Investigator

Trikalinos, Nikolaos

Disease Site

Anus; Breast; Cervix; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Stomach; Urinary Bladder

Learn more about this study at: clinicaltrials.gov